Gufic Biosciences Q1 FY27 earnings call

Gufic Biosciences reported a robust Q1 FY27, with total revenue from operations growing 14.95% year-on-year to INR260.8 crores, up from INR226.9 crores in Q1 FY26. EBITDA saw a significant 42.17% YoY increase, reaching INR47.2 crores, which led to an EBITDA margin expansion to 18.09% from 14.6% in the previous year. Profit after tax (PAT) surged 85.61% YoY to INR22.46 crores, with the PAT margin improving to 8.61% from 5.3% in Q1 FY26. Quarter-on-quarter, revenue grew 3.45% and PAT grew 9.02%.

The Indore plant is now fully operational, with qualification and validations complete, and product tech transfers progressing as planned. The depot and microsphere suite are nearing completion, enabling in-house manufacturing of long-acting depot presentations. Management expects Indore's capacity utilization to reach 40-45% by the end of FY27. The suspension and liquid vial lines at Indore are targeted to achieve close to 80% capacity utilization within the next three years, contributing to future operating leverage.

In Critical Care, Gufic launched its monobactam and beta-lactamase inhibitor combination immediately after the innovator patent expiry, observing early acceptance in large institutions. The women's health segment saw Ferticare maintain its leadership, and the Puregraf group secured entry into major corporate IVF chains. In aesthetics, the company partnered with Revanesse Prollenium for fillers, targeting an Indian market launch by December/January after registration by Q2/mid-Q3 FY27. The botulinum toxin (Stunnox/Zarbot) is in the process of registration in several countries, with current facility limitations guiding initial focus on Southeast Asian and African markets.

Gufic is transitioning its international model from distributor-led to an IP-led/B2C approach in emerging markets like Africa, Southeast Asia, and South Asia. This strategy involves building dedicated front-end teams to capture higher margins, aiming for 15-20% more than current 40-50% margins, and owning the IP/trademarks. The company also progressed licensing in Europe, executed a contract manufacturing and licensing arrangement with a North American counterparty, and received its first contract manufacturing orders in Australia, indicating a broader global reach.

Gufic's GLP-1 manufacturing for Hetero is strictly a Contract Manufacturing Organization (CMO) arrangement, with no front-end plans for Gufic in India or abroad. After a 10-15 day plant shutdown in Q1 for new machine installation, CMO operations are expected to gain significant traction from Q2, with actual traction anticipated in Q3 FY27. This segment is projected to contribute to the company's overall 15% year-on-year growth target, leveraging the partnership with Hetero.

The EBITDA margin improved to 18.09% in Q1 FY27, which management views as the start of an improving trend. The previous margin drop in Q3/Q4 2025 was attributed to the capitalization of Indore facility expenses. With increasing capacity utilization at Indore and a strategic shift towards a higher-value product mix (targeting 20% liquid, 50-60% lyophilization, 20-30% complex injectables), operating leverage gains are expected to start kicking in by mid-FY28. The company aims for a maximum revenue potential of INR1,600-2,000 crores from its existing facilities without further major capex.

Gufic has partnered with the CHAI Foundation for liposomal amphotericin B, a collaboration expected to facilitate access to over 100 markets globally. Bioequivalent studies for this product are underway, with WHO PQ submission planned. This partnership leverages Gufic's Navsari facility and future integration with Indore, aligning with the company's strategy to expand its therapeutic reach beyond core neurology into urology, ophthalmology, and pain management.